Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia

CONCLUSIONS: The Gilteritinib-based regimen shows a high and sustained therapeutic effect with minimal adverse effects, and provides a valuable experience for further evaluation in EMR APL patients.PMID:38095349 | DOI:10.1080/16078454.2023.2293496

Source: Hematology - December 14, 2023 Category: Hematology Authors: Chun-Xiao Hou Yu Chen Shan-Hao Liu Yi-Zhi Jiang Dong-Ping Huang Su-Ning Chen Source Type: research